The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis

BACKGROUND: Ocrelizumab is approved for the treatment of both relapsing and progressive multiple sclerosis (MS). OBJECTIVE: To examine the impact of ocrelizumab on health-related quality of life (HRQOL) in individuals with MS. METHODS: Ninety-eight individuals with relapsing and 32 with progressive...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mult Scler J Exp Transl Clin
Autors principals: Glanz, Bonnie I, Zurawski, Jonathan, Casady, Emily C, Shamah, Rebecca, Weiner, Mira, Chitnis, Tanuja, Weiner, Howard L, Healy, Brian C
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2021
Matèries:
Original Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8138295/
https://ncbi.nlm.nih.gov/pubmed/34046184
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/20552173211007523
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars